Why it matters: CurveBeam raised $25 million at 48¢ a share valuing it at $153.7 million.
Fund managers such as SG Hiscock have backed the med tech float.
Medical imaging technology business CurveBeam AI has convinced fund managers to back its ASX debut with the prospect of strong sales growth in the US healthcare market predicated on more accurate osteoarthritis diagnoses.
The software developer, which had its origins at Melbourne University in 2009, will float on Wednesday after raising $25 million at 48¢ a share in its initial public offering, for an implied market value of $153.7 million.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com